Sorrento Therapeutics (SRNE) Posts Q3 GAAP Loss of 27c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts SRNE Hot Sheet
Join SI Premium – FREE
Sorrento Therapeutics (NASDAQ: SRNE) reported Q3 EPS of ($0.27), which may not compare with the analyst estimate of ($0.32). Revenue for the quarter came in at $1.28 million versus the consensus estimate of $760 thousand.
For earnings history and earnings-related data on Sorrento Therapeutics (SRNE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JetBlue shares jump on Q3 results and 2027 outlook
- Novartis (NVS) Tops Q3 EPS by 18c; offers guidance
- German American Bancorp (GABC) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
